Back to Search
Start Over
Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population
- Source :
- OncoTargets and therapy
- Publication Year :
- 2018
-
Abstract
- Jia-Yan Ni,1,* Shan-Shan Liu,2,* Hong-Liang Sun,1 Wei-Dong Wang,1 Ze-Long Zhong,1 Si-Nan Hou,1 Yao-Ting Chen,1 Lin-Feng Xu1 1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Interventional Radiology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, People’s Republic of China; 2Department of Public Health, Sushe Community Health Service Center, Guangzhou 510220, Guangdong Province, People’s Republic of China *These authors contributed equally tothiswork Objective: To compare the clinical efficacy and safety of transcatheter hepatic arterial infusion chemotherapy (HAIC) with those of sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) of Barcelona Clinic Liver Cancer (BCLC) stage C. Methods: Potentially relevant studies comparing the clinical efficacy and safety of HAIC with those of sorafenib were searched using Medline, PubMed, Embase, Cochrane Library, and Chinese databases (Wanfang Data and China National Knowledge Infrastructure). Overall survival rate (OSR), tumor response rate, disease control rate (DCR), and serious adverse events (SAEs) were compared and analyzed. Pooled ORs with 95% CIs were calculated using either the fixed-effects model or the random-effects model. All statistical analyses were conducted using Review Manager (version 5.3) from the Cochrane Collaboration. Results: A total of 1,264 patients were included in this meta-analysis. The results of this study showed that HAIC was associated with significantly higher 1-, 2-, and 3-year OSRs than sorafenib (OR 1.88, 95% CI1-year: [1.27–2.78], P1-year=0.002; OR 2.15, 95% CI2-year: [1.06–4.37], P2-year=0.03; OR 7.90, 95% CI3-year: [2.12–29.42], P3-year=0.002). Compared to sorafenib, HAIC was associated with superior complete response (CR), partial response (PR), and objective response rate (ORR) (OR 3.90, 95% CICR: [1.89–8.03], PCR =0.0002; OR 3.47, 95% CIPR: [2.31–5.24], PPR
- Subjects :
- Sorafenib
medicine.medical_specialty
Cochrane Library
Gastroenterology
OncoTargets and Therapy
03 medical and health sciences
0302 clinical medicine
Internal medicine
Medicine
Pharmacology (medical)
Stage (cooking)
HCC
Adverse effect
Original Research
business.industry
medicine.disease
targeted therapy
BCLC Stage
HAIC
BCLC
meta-analysis
Oncology
030220 oncology & carcinogenesis
Hepatocellular carcinoma
030211 gastroenterology & hepatology
prognosis
business
Liver cancer
Progressive disease
medicine.drug
Subjects
Details
- ISSN :
- 11786930
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- OncoTargets and therapy
- Accession number :
- edsair.doi.dedup.....5afa60c4f0bacf06200a1aa95e5e0b64